Physician profile
Scott Blumenthal
NPI 1922199843
$5,423.68
in general payments reported to CMS, 2019-2025
54 companies · $586 in 2025
The $586 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $454 · 2021: $775 · 2022: $728 · 2023: $576 · 2024: $595 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $649.14 | 2019-2025 | |
| Abbvie INC. | $599.96 | 2019-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $333.74 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $320.80 | 2019-2024 | Nuplazid |
| Allergan, INC. | $308.88 | 2019-2020 | |
| Ucb, INC. | $270.62 | 2019-2022 | |
| Lundbeck LLC | $241.15 | 2019-2025 | Vyepti, Rexulti |
| Celgene Corporation | $203.49 | 2021-2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $192.82 | 2020-2022 | |
| Emd Serono, INC. | $185.71 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $171.92 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $159.36 | 2019-2023 | Ultomiris |
| Mdd US Operations, LLC | $140.15 | 2019-2024 | Apokyn, Apokyn |
| Supernus Pharmaceuticals, INC. | $130.47 | 2020-2022 | |
| Eisai INC. | $115.51 | 2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Blumenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.